Everyday counts: time to patient access to innovative oncology therapies in Europe
- What factors delay access to new cancer medicines across Europe?
- Which best practices and what recommendations can improve time to patient access?
- Applying an unbiased, multi-stakeholder perspective
- Ensuring an academic robustness of research methodologies
- Focusing on tangible solutions with impact, co-created with all relevant stakeholders.
Figure 1 Time between EMA approval and reimbursed access to new oncology medicines. Source: EFPIA W.A.I.T. Indicator, 2018
 M. Aitken, M. Kleinrock, and S. Kumar, “Global Oncology Trends 2017. Advances, Complexity and Cost,” QuintilesIMS Inst., no. June, pp. 1–40, 2017
 EFPIA Patient W.A.I.T. Indicator 2018 survey. “Patients W.A.I.T.” stands for Patients Waiting to Access Innovative Therapies. The INDICATOR provides a benchmark of the rate of availability and waiting times in European countries;
 Allemani, C., Matsuda, T., Di Carlo, V., Harewood, R., Matz, M., Niksic, M., et al., Global surveillance of trends in cancer survival 2000-2014.